Chemours Company

▲ Bull Case

• ◆Opteon Wide-Moat Recognition Drives SOTP Re-Rating—Opteon generates ~55-65% of company EBITDA but trades inside blended TiO2-commodity multiple of 5-7x. As Opteon grows to ~$700-800M EBITDA by 2027-2028 under AIM Act demand pull, market eventually grants 12-15x spec-chem multiple, unlocking $40-90/share SOTP value.
• ◆TiO2 Cycle Recovers to Mid-Cycle—Historical TiO2 cycles (post-2012, post-2016) saw volume recoveries of 30-50% within 18-24 months of trough. Base model conservatively projects volume recovery of 22% (685kMT → 835kMT). Each $100/MT ASP recovery = ~$80-90M EBITDA; combined volume + price recovery supports +$25-35/share even before any Opteon re-rating.
• ◆PFAS Settles at Lower End of Range—June 2023 water utility settlement structurally capped one major class of claims. If state AGs settle at midpoint or below (~$2.0B all-in NPV vs. consensus $3-3.5B), reverse-DCF math shows ~$5-8/share of locked-in PFAS-discount narrowing—positive variant against current implied pricing.

▼ Bear Case

• ◆Opteon Patent Cliff Arrives Sooner Than Bulls Assume—Core HFO-1234yf patents begin expiring 2025-2030. Daikin has stated HFO ambitions; Chinese chemical companies have HFO capability. If 2027 onset competition compresses HFO pricing 25%, TSS EBITDA falls ~$150-200M permanently, eliminating the spec-chem-multiple thesis entirely.
• ◆PFAS Liability Materially Exceeds Expectations—EPA's 2024 PFAS National Primary Drinking Water Regulation (4 ppt MCL) + potential Superfund designations expand regulatory framework. Additional state AG settlements at $700M-1B+ each could push total Chemours PFAS NPV to $4-7B+—exceeding equity market value.
• ◆Cyclical Stall + Leverage = Dilution Risk—Combined recession (10-15% TiO2 demand drop) + delayed Opteon ramp + Term Loan B refi at higher rates pushes Net Leverage above 4.5x, triggering covenant negotiations and forcing equity issuance at depressed prices. A $1B raise at $15/share = +33% dilution, permanently impairing per-share value.

“The Street debate is fundamentally about multiple, not earnings. EBITDA path: Sell-side consensus FY2026 EPS is $1.45 vs. our model $3.22; delta reflects management guide of FY2026 EBITDA $800-900M (well below our $1.19B). Multiple framework: Should Opteon's ~$500M+ EBITDA stream get a spec-chem multiple (12-16x) or stay blended into commodity (5-7x)? This is the re-rating debate. PFAS NPV: Bears assume $3-5B; bulls assume $1.5-2.5B; each $500M delta = ~$3/share. Patent cliff timing: 2026 (early) vs. 2030 (gradual). Both sides have defensible arguments; investment merit is the asymmetry (right-tail bull / left-tail bear), not that bull case is clearly correct.”

• ◆AIM Act Phase 2 HFC allocation cuts (Jan 2025 ongoing)—+$50-100M/yr TSS EBITDA step-up as regulatory supply reductions mechanically drive Opteon volume growth
• ◆TiO2 ASP and volume recovery confirmation (Q2-Q3 2025)—Each $100/MT ASP recovery = +$80-90M EBITDA; volume recovery to 750kMT+ annualized indicates cycle acceleration
• ◆SEC inquiry resolution (2025)—No enforcement or fine-only outcome triggers +5-15% stock re-rating and institutional re-engagement
• ◆Opteon XP stationary commercial scale (2025-2026)—Expansion of TAM beyond mobile AC to commercial HVAC triggers TSS multiple re-rating debate
• ◆PFAS state settlement progress (2025-2026)—Each settlement outcome <$300M Chemours share validates PFAS floor and base-case pricing

• ◆PFAS existential tail (~5% probability)—EPA Superfund expansion, $1B+ state AG settlements, or new contamination revelation pushes PFAS NPV to $4-7B+, exceeding equity market value
• ◆Opteon patent cliff + Daikin/Chinese HFO competition (2026-2030, 25% probability)—Commercial-scale HFO-1234yf supply compresses HFO pricing 25%+, eliminates spec-chem-multiple thesis and $15-25/share of value
• ◆TiO2 structural impairment from Chinese chloride capacity (20% probability)—Low-cost Chinese TiO2 expansion caps ASP recovery, reduces through-cycle EBITDA by $100-150M
• ◆Macroeconomic recession with TiO2 demand destruction (25% probability)—10-15% volume drop + delayed Opteon ramp compresses EBITDA below $900M, invalidates base model
• ◆Dilutive equity raise forced by covenant stress (15% probability)—Net Leverage >4.5x triggers refinancing and forces $500M-1B issuance at <$15/share, permanently impairs per-share intrinsic value